Startups
2016
ALBAJUNA THERAPEUTICS SLDevelopment of therapeutic antibodies against HIV
Address
Avinguda de la Generalitat 152, 08174 Sant Cugat del Vallès, Spain
CERCA ownership
Badalona, Spain
1995
Institut de Recerca de la Sida (IRSICAIXA)
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the "natural killer" cells responsible for destroying cells infected by the virus
Product description
Developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the "natural killer" cells responsible for destroying cells infected by the virus.The three candidate molecules available have demonstrated in vitro results that are 100 times more powerful than those obtained to date by any other molecule with similar characteristics.
The in vitro results of the candidate molecules have demonstrated a neutralizing power 100 times greater than that of any other molecule developed to date, and the participation of Grifols in this research company will accelerate its development.
The in vitro results of the candidate molecules have demonstrated a neutralizing power 100 times greater than that of any other molecule developed to date, and the participation of Grifols in this research company will accelerate its development.